Opko Health Inc (NASDAQ: OPK) closed the day trading at $1.05 up 5.37% from the previous closing price of $1.00. In other words, the price has increased by $+0.0535 from its previous closing price. On the day, 10288598 shares were traded. OPK stock price reached its highest trading level at $1.0700 during the session, while it also had its lowest trading level at $0.9900.
Ratios:
For a better understanding of OPK, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.44 and its Current Ratio is at 1.78. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.18.
On December 15, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $3.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 21 when FROST PHILLIP MD ET AL bought 1,000,000 shares for $0.99 per share. The transaction valued at 991,700 led to the insider holds 208,368,225 shares of the business.
FROST PHILLIP MD ET AL bought 1,500,000 shares of OPK for $1,462,800 on Feb 07. The CEO & Chairman now owns 207,368,225 shares after completing the transaction at $0.98 per share. On Jan 29, another insider, KRASNO RICHARD M, who serves as the Director of the company, bought 30,000 shares for $0.99 each. As a result, the insider paid 29,838 and bolstered with 103,333 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OPK now has a Market Capitalization of 724.87M and an Enterprise Value of 894.07M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.84 while its Price-to-Book (P/B) ratio in mrq is 0.56. Its current Enterprise Value per Revenue stands at 1.03 whereas that against EBITDA is -9.42.
Stock Price History:
Over the past 52 weeks, OPK has reached a high of $2.24, while it has fallen to a 52-week low of $0.85. The 50-Day Moving Average of the stock is 1.1560, while the 200-Day Moving Average is calculated to be 1.5109.
Shares Statistics:
Over the past 3-months, OPK traded about 11.24M shares per day on average, while over the past 10 days, OPK traded about 6.42M shares per day. A total of 772.65M shares are outstanding, with a floating share count of 366.90M. Insiders hold about 47.36% of the company’s shares, while institutions hold 27.24% stake in the company. Shares short for OPK as of Jan 31, 2024 were 97.07M with a Short Ratio of 8.63, compared to 26.98M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 13.93% and a Short% of Float of 26.70%.
Earnings Estimates
Current recommendations for the stock of the company come from 5 analysts. On average, analysts expect EPS of -$0.09 for the current quarter, with a high estimate of -$0.08 and a low estimate of -$0.1, while EPS last year was -$0.11. The consensus estimate for the next quarter is -$0.06, with high estimates of -$0.05 and low estimates of -$0.08.
Analysts are recommending an EPS of between -$0.24 and -$0.26 for the fiscal current year, implying an average EPS of -$0.25. EPS for the following year is -$0.19, with 6 analysts recommending between -$0.01 and -$0.29.
Revenue Estimates
6 analysts predict $177.53M in revenue for the current quarter. It ranges from a high estimate of $180M to a low estimate of $174.8M. As of the current estimate, Opko Health Inc’s year-ago sales were $185.4M, an estimated decrease of -4.20% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $193.17M, a decrease of -18.70% less than the figure of -$4.20% in the same quarter last year. There is a high estimate of $202.18M for the next quarter, whereas the lowest estimate is $186M.
A total of 6 analysts have provided revenue estimates for OPK’s current fiscal year. The highest revenue estimate was $861.59M, while the lowest revenue estimate was $856.4M, resulting in an average revenue estimate of $859.13M. In the same quarter a year ago, actual revenue was $1B, down -14.40% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $840.89M in the next fiscal year. The high estimate is $1.04B and the low estimate is $784M. The average revenue growth estimate for next year is down -2.10% from the average revenue estimate for this year.
